英科醫療(300677.SZ):擬參與投資蘇州維新鈦氪創業投資合夥企業
格隆匯10月17日丨英科醫療(300677.SZ)公佈,為進一步優化投資結構,提升投資價值,公司擬簽署《蘇州維新鈦氪創業投資合夥企業(有限合夥)有限合夥合同》,以自有資金投資蘇州維新鈦氪創業投資合夥企業(有限合夥)(“合夥企業”或“基金”)。合夥企業的認繳出資總額為不超過5億元人民幣,本輪認繳出資總額為1.6億元,其中,公司將作為該合夥企業的有限合夥人(LP)認繳出資3000萬元。
本合夥企業擬主要對新一代信息技術產業等戰略新興產業進行價值投資,實現長期資本升值,力爭實現本合夥企業投資利益的最大化和有限合夥人的最佳利益回報。
公司此次投資合夥企業,可以結合合夥企業在新一代信息技術產業等戰略新興產業的相關經驗和資源,拓展公司的投資渠道,獲取長期投資收益。此外,公司也將積極關注上述領域中在業務方面潛在的合作機會,爭取將協同效應最大化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.